Genfit’s PPAR agonist fails to resolve NASH Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) fell $10.88 (49%) to $11.22 in after-hours trading Monday after reporting that dual PPARα/δ agonist elafibranor missed the primary endpoint of the Phase III...

ImmunoMolecular Therapeutics LLC’s small molecule inhibitor of an HLA-DQ8 peptide could treat Type I diabetes without courting the broad-spectrum immunosuppression of other disease-modifying therapies in development. About 60% of Type I diabetes patients carry the...

By sourcing T cells directly from the pancreatic islets of Type I diabetes patients, rather than the standard method of taking blood samples, an academic team has provided an unprecedented view into the molecules that...

Armed with positive Phase IIa data in Type I diabetes, Tolerion Inc. is now seeking funding for a second go at developing a selective immunomodulatory approach that previously failed in multiple sclerosis. In 2011, Tolerion...

A blinded, dose-escalation Phase II trial in 80 adult Type I diabetics showed that all doses of once-weekly intramuscular TOL-3021 for 12 weeks improved C-peptide levels, a marker of pancreatic beta cell function, relative to...

Tolerion Inc. (Portola Valley, Calif.) said all doses of once-weekly intramuscular TOL-3021 for 12 weeks improved C-peptide levels, a marker of pancreatic beta cell function, relative to placebo in a Phase II trial to treat...

FDA granted Orphan Drug designation for Tolera's TOL101 to treat Type I diabetes in patients ages 16 years or younger with preserved pancreatic beta-cell function. The mAb against alpha beta T cell receptor is in...

Corporate Profile Tolera Therapeutics Inc. is developing a mAb against the alpha beta T cell receptor designed to improve upon the safety and tolerability of Genzyme Corp. 's Thymoglobulin , the market-leading antibody for induction therapy...

FDA granted Orphan Drug designation for Tolera'sTOL101 to prevent acute rejection of solid organ transplantation. The mAb against T cells is in Phase II testing for the indication. Tolera Therapeutics Inc. , Cleveland, Ohio Product: TOL101...